<DOC>
	<DOCNO>NCT03056495</DOCNO>
	<brief_summary>This Clinical Trial open , non-randomized Phase Ib study determine maximal tolerable dose ( MTD ) Vorinostat Alzheimer disease ( AD ) patient ( include ) 55 90 year mild symptom . The MTD study define dose lead maximum toxicity Common Toxicity Criteria ( CTC ) grade 1 symptoms.The safety tolerability Vorinostat group study participant test .</brief_summary>
	<brief_title>Clinical Trial Determine Tolerable Dosis Vorinostat Patients With Mild Alzheimer Disease</brief_title>
	<detailed_description>The MTD Vorinostat treatment Alzheimer 's patient determine use open , non-randomized , multicentric dose-finding study adaptive design . This Clinical Trial take place 2 part . The first part perform dose escalation part cohorts three subject . Possible dosage : one , two , three four capsule ( 100 mg per capsule ) per day . The first cohort receives dose 100 mg per day . After treatment , Vorinostat-free follow-up phase take place . For follow cohort , dose increase , repetition previous dose dose reduction possible . After dose escalation determination MTD , dosage confirmation carry additional subject . The subject give dose Vorinostat MTD 4 week follow Vorinostat-free follow-up phase .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>write informed consent participate study verify capacity consent doctor involve study mild Alzheimer 's disease ( NINCDS / ADRDA criterion MiniMental State Examination ( MMSE ) 2227 ) age ( include ) 55 90 year subject must able meet requirement describe study protocol outpatient living Informant live subject household Rosen modify Hachinski ischemia score ≤4 concern female patient : postmenopausal concern male patient : commitment use suitable contraceptive cerebral imaging study ( CT cMRI ) , consistent diagnosis probable Alzheimer 's disease ( old 3 year ) neurological psychiatric disease explain cognitive deficit well AD diagnosis conspicuous MRI / CCT scan explain cognitive deficit well AD diagnosis severe physical , neurological psychiatric disorder interfere participation study history malignant tumor except non metastasize basal cell carcinoma skin history seizure dysphagia lead inability swallow capsule untreated severe acute infection clinical symptom respiratory infection , pneumonia , bronchitis , acute diarrhea , influenza , untreated urinary tract infection family history , unexplained sudden case heart failure age 50 year long QT syndrome family history evidence QTc prolongation ≥480 m screening ( Fridericia adjust QT interval ) , arrhythmias especially severe uncontrolled ventricular arrhythmias atrial fibrillation ECG sufficiently treat angina heart failure ( NYHA III , IV ) myocardial infarction know infection HBV , HCV / HIV occurrence venous thrombosis embolism therapy antidepressant begin last 12 week dose modification preexist therapy antidepressant antidiabetic treatment begin last 12 week dose modification preexist antidiabetic treatment longterm use antiinflammatory drug except acetylsalicylic acid cardiovascular prophylaxis current treatment treatment within past 12 week HDAC inhibitor ( eg valproate ) take medication may increase dosedependent side effect myelosuppression QTc interval prolongation . These include , limited : Class Ia antiarrhythmic agent quinidine , procainamide , disopyramide Class III antiarrhythmic drug amiodarone , sotalol , ibutilide Class Ic antiarrhythmic flecainide , propafenone penicillamine opioids methadone pyrazolone derivative metamizole Propyphenazone doxorubicin , epirubicin macrolides analogue erythromycin , clarithromycin telithromycin oxazolidinones linezolid quinolones moxifloxacin , levofloxacin fluoxetine , maprotiline tricyclic tetracyclic antidepressant chlorpromazine , pimozide , haloperidol , droperidol , ziprasidone clozapine antiemetic azole like ketoconazole , fluconazole , voriconazole aminocholine primaquine pentamidine quinine , chloroquine diaminopyrimidine pyrimethamine salbutamol formoterol methotrexate azathioprine , cyclosporine Interferon gamma 1b alemtuzumab , basiliximab , efalizumab , natalizumab sunitinib , nilotinib , lapatinib mitoxantrone , Hydroxycarbamide , mercaptopurine take prescription nonprescription drug cognitive enhancement ( except cholinesterase inhibitor memantine stable dose least 3 month baseline ) therapy anticoagulant except acetylsalicylic acid HbA1c screen 10 % upper limit normal magnesium , sodium , calcium potassium level outside normal range ( screen baseline ) exist anemia Hb &lt; 11 ( screen baseline ) exist thrombocytopenia ; platelet ≤150.000 / ul , leukocytes ≤ 3.000 / ul , neutrophils absolutely ≤ 1.500 / ul ( screen baseline ) prothrombin INR ≥ 1.5 laboratory limit normal ; PTT ≥ 1.5 x laboratory limit normal ( screen baseline ) clinically relevant renal / hepatic impairment screen baseline ( total bilirubin ≥ 1.5 x upper limit norm / GPT , AST ≥ 4x upper limit norm / creatinine ≥ 1.5x upper limit norm / creatinine clearance &lt; 60 ml / min ) hematuria &gt; 15 RBCs / mL screen baseline proteinuria screen baseline except asymptomatic urinary tract infection participate clinical therapeutic trial within last 12 week relevant dose confirmation : subject exist contraindication perform MRI MRI available period 6 month prior screen cardiac pacemaker metal object body , exclude 1.5 3 T MRI claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>